Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab and Cemiplimab in Recurrent or Progressive High-Grade Glioma or Ependymoma
NCT07567469Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Aug 2032
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of fianlimab in glioma, ependymoma, sponsored by Regeneron Pharmaceuticals. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
fianlimab
03
Conditions
gliomaependymoma
Beyond the preview
Go deeper on NCT07567469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567469.